We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

48 hedge funds and large institutions have $44.9M invested in Acrivon Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

37% more capital invested

Capital invested by funds: $32.7M → $44.9M (+$12.2M)

3.27% more ownership

Funds ownership: 55.71% → 58.98% (+3.3%)

0% more funds holding

Funds holding: 48 → 48 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
48
Holders Change
–
Holders Change %
0%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
16
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.06M
2
Marshall Wace
Marshall Wace
United Kingdom
+$753K
3
Two Sigma Investments
Two Sigma Investments
New York
+$578K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$429K
5
Citadel Advisors
Citadel Advisors
Florida
+$219K

Top Sellers

Rank Fund Capital Flow
1
Focus Partners Wealth
Focus Partners Wealth
Massachusetts
-$988K
2
UBS Group
UBS Group
Switzerland
-$728K
3
BlackRock
BlackRock
New York
-$274K
4
Squarepoint
Squarepoint
New York
-$170K
5
Millennium Management
Millennium Management
New York
-$138K
Name Holding Trade Value Shares
Change 		Change in
Stake
QC
26
Quadrature Capital
United Kingdom
$50K +$45.1K +20,730 New
XT
27
XTX Topco
Cayman Islands
$49.6K -$33.4K -15,383 -43%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$44.3K -$2.64K -1,215 -6%
VWWMG
29
Vermillion & White Wealth Management Group
Pennsylvania
$43.6K +$39.3K +18,100 New
Bank of America
30
Bank of America
North Carolina
$42K -$3.17K -1,457 -8%
JP Morgan Chase
31
JP Morgan Chase
New York
$40.6K +$32.9K +15,123 +869%
SSA
32
Schonfeld Strategic Advisors
New York
$39.6K +$35.7K +16,428 New
Citigroup
33
Citigroup
New York
$35.2K -$3.72K -1,713 -11%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$30K +$27K +12,433 New
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$26.2K +$23.6K +10,876 New
AWM
36
AAF Wealth Management
Massachusetts
$25.7K – – –
MG
37
Marex Group
$24.1K +$21.7K +10,000 New
Fidelity Investments
38
Fidelity Investments
Massachusetts
$20.8K – – –
Federated Hermes
39
Federated Hermes
Pennsylvania
$13.5K +$6.93K +3,186 +131%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$4K +$1.66K +763 +80%
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$1.53K -$1.21K -555 -47%
Nisa Investment Advisors
42
Nisa Investment Advisors
Missouri
$1.41K – – –
RPA
43
Redwood Park Advisors
California
$1.21K – – –
Russell Investments Group
44
Russell Investments Group
United Kingdom
$1.16K – – –
FDCDDQ
45
Federation des caisses Desjardins du Quebec
Quebec, Canada
$964 – – –
EWA
46
EverSource Wealth Advisors
Alabama
$899 – – –
OC
47
Optima Capital
Oregon
$670 +$604 +278 New
SS
48
SBI Securities
Japan
$178 – – –
AG
49
Algert Global
California
– -$81K -44,648 Closed
BCM
50
Bluefin Capital Management
New York
– -$76.1K -42,039 Closed
1
2
3

ACRV Hedge Fund Activity: Q4 2025 in Review

48 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2025, worth a combined $44.9M — up 37% from $32.7M a quarter earlier.

Fund positioning in ACRV was balanced in Q4 2025: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 10 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $1.06M. The largest seller was Focus Partners Wealth, exiting entirely with an estimated $988K sold.

  • 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $44.9M of Acrivon Therapeutics stock for Q4 2025, up 37% quarter-over-quarter.
  • 8 funds opened new Acrivon Therapeutics positions in Q4 2025 and 8 closed out, a net change of 0 holders.
  • The largest Acrivon Therapeutics buyer in Q4 2025 was Acadian Asset Management, an estimated $1.06M added.
  • The largest Acrivon Therapeutics seller in Q4 2025 was Focus Partners Wealth, an estimated $988K sold.

Based on aggregated 13F filings for Q4 2025.